ABSTRACT
Primary cutaneous acral CD8+ T-cell lymphoma (PCACTL) is currently a provisional entity defined as a rare cutaneous proliferation of atypical CD8+ lymphocytes that preferentially involves acral sites and has a good prognosis. We present a case of primary cutaneous CD8+ T-cell lymphoma involving the eyelid of an adolescent male. The case shares features with PCACTL, including indolent clinical behavior and expression of CD68 in a Golgi-associated dot-like pattern; however, other features differ significantly from PCACTL as currently defined by the World Health Organization (WHO). These features include ulceration, expression of CD56, granzyme B, and perforin, and a high proliferative index. Given these discrepancies, our case is currently best classified as a CD8+ primary cutaneous peripheral T-cell lymphoma, not otherwise specified. We review the differential diagnosis for this case and suggest expanding the definition of PCACTL.
Subject(s)
CD8-Positive T-Lymphocytes/pathology , Eyelid Neoplasms/pathology , Lymphoma, T-Cell, Cutaneous/pathology , Skin Neoplasms/pathology , Adolescent , Eyelid Neoplasms/immunology , Humans , Lymphoma, T-Cell, Cutaneous/immunology , Male , Skin Neoplasms/immunologyABSTRACT
BACKGROUND: Mohs micrographic surgery, excisional surgery, and electrodessication and curettage (ED&C) are common dermatologic procedures that often use electrodessication through hyfrecators to achieve hemostasis. According to in vitro studies, electrodessication is considered safe in patients with implanted cardiac devices. To the authors' knowledge, there are no in vivo data to support this claim. OBJECTIVE: In this study, the authors aim to describe the outcomes of hyfrecation during dermatologic procedures in patients with pacemakers and implantable cardiac devices. METHODS: Retrospective chart review was completed from March 2014 to April 2018 at a single center. Forty-five patients met criteria of having a cardiac device and having undergone an electrosurgery procedure using the Conmed 2000 Hyfrecator (Utica, NY). Adverse perioperative and postoperative outcomes, as well as device malfunction, were evaluated. RESULTS: No adverse perioperative effects were reported. Device reports were examined for inappropriate firing of the defibrillator, loss of capture, temporary inhibition of pacing, battery drainage, pacing at an elevated or erratic rate, failure to deliver antitachycardia, reversion to asynchronous pacing, induction of arrhythmias, or tissue damage at lead tissue, but no such issues were found. CONCLUSION: The lack of complications associated with cardiac devices with hyfrecation is reassuring. However, prospective and larger retrospective studies are warranted.
Subject(s)
Defibrillators, Implantable , Electrosurgery/instrumentation , Hemostasis, Surgical/instrumentation , Mohs Surgery/instrumentation , Pacemaker, Artificial , Skin Diseases/surgery , Aged , Female , Humans , Male , Retrospective Studies , Risk FactorsSubject(s)
Carcinoma, Basal Cell/surgery , Facial Neoplasms/surgery , Myocutaneous Flap , Occupational Diseases/surgery , Skin Neoplasms/surgery , Wound Closure Techniques , Carcinoma, Basal Cell/pathology , Chin , Facial Neoplasms/pathology , Humans , Male , Middle Aged , Mohs Surgery , Neck , Neoplasm Invasiveness , Occupational Diseases/pathology , Skin Neoplasms/pathology , WeldingABSTRACT
Long-term sequelae due to extravasation of intravenous radioisotopes resulting in radiation injuries are rarely reported. As the use of radioactive isotopes for the treatment of osteoblastic metastases increases, information regarding the prevention, treatment, and long-term monitoring of suspected extravasation injury will become increasingly important. We present a patient with no previous history of skin cancer who developed an aggressive cutaneous squamous cell carcinoma at the site of prior radium-223 extravasation. We recommend that patients who experience extravasation of therapeutic radioisotopes be monitored by dermatologists for long-term sequelae. Cutaneous squamous cell carcinoma should be recognized as a rare but potential adverse event following cutaneous extravasation of radium-223 and is likely a side effect that is severely underreported.